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Small molecule selectin ligand inhibition improves outcome in genesis of renal ischemia-reperfusion injury (IRI) have
ischemic acute renal failure. most commonly utilized the model of renal artery clamp-
Background. The pathophysiologic and potential therapeu- ing. Post-ischemic renal injury in this model has beentic role of selectins in renal ischemia-reperfusion injury (IRI)
shown to be very similar to human ischemic renal injury,is not fully understood, due in part to redundancy in the roles
including that secondary to cold kidney storage prior toof individual selectins. We hypothesized that blockade of ligands
for all three selectins using a novel small molecule (TBC-1269) transplantation [5, 6]. However, a recent review also has
would improve the course of renal IRI by overcoming redun- emphasized differences between experimental animal
dancy issues. This was investigated in a rat model of renal IRI. and human acute renal failure [7].Methods. Rats were treated with TBC-1269 either during
Several studies have shown that ischemia-reperfusionor post-IRI. The effects of TBC-1269 were investigated in two
can stimulate renal expression of leukocyte adhesionmodels of renal IRI: moderate IRI (30 minutes bilateral renal
artery clamping) and severe IRI (45 minutes clamping). The molecules [8, 9]. Previous studies have demonstrated
combination of anti-E- and anti-P-selectin antibodies also was that antibody blockade of the CD11/CD18 receptor on
investigated in rats subjected to moderate IRI. Renal function, leukocytes significantly attenuated renal IRI in ratshistological injury and mortality were assessed.
[8, 10]. Moreover, antibody blockade of intercellular ad-Results. Rats treated with TBC-1269 during moderate IRI
hesion molecule (ICAM-1), a ligand for CD11/CD18,showed significantly reduced serum creatinine (SCr) and tubular
necrosis post-ischemia compared to control animals. By con- provided even greater protection [8, 11–13].
trast, delayed treatment (post-IRI) did not show a reduction Leukocyte rolling on the endothelium, which precedes
in SCr. In rats with severe IRI, TBC-1269 treatment during IRI firm adhesion via CD11/CD18 and ICAM-1, is mediatedsignificantly reduced mortality at 48 hours post-ischemia. Rats
by a class of adhesion molecules known as selectins [14].with moderate IRI and treated with the combination of anti-
The selectin family consists of three different transmem-E- and anti-P-selectin antibodies showed significantly reduced
SCr compared to control rats at 24 hours post-ischemia. brane receptors, E-, P- and L-selectin [14, 15]. The selec-
Conclusions. Small molecule selectin ligand inhibition pro- tins bind to sialylated and fucosylated receptors related
vides a novel and effective approach to attenuate ischemic to the Lewis X blood group antigen, and have significantacute renal failure. Timing of treatment is crucial to success.
modulatory effects on cellular functions independent of
adhesion [14]. E-selectin is expressed on cytokine-stimu-
lated endothelium [15]. P-selectin is expressed on plate-
Ischemic acute renal failure is the most common cause
lets and activated endothelial cells, and appears to haveof delayed renal allograft function (DGF) and is also
some inducers different from those of E-selectin [14].associated with high (50%) mortality in patients with
L-selectin is constitutively expressed on lymphocytes,native kidneys [1–4]. Experimental studies of the patho-
neutrophils, monocytes and other myeloid cells, and me-
diates lymphocyte adhesion to high endothelial venules
and peripheral lymph nodes [14].Key words: leukocytes, disease models, kidney failure, delayed graft
function, transplantation, cold kidney storage, renal artery clamping. Selectin blockade has been found to attenuate IRI in
skeletal muscle, ear and myocardium [16–18] and alsoReceived for publication January 23, 2001
may in the kidney. We found that L-selectin was a redun-and in revised form June 18, 2001
Accepted for publication July 13, 2001 dant and ineffective target for treatment of murine renal
IRI, though it was important in reducing peritoneal in- 2001 by the International Society of Nephrology
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Fig. 1. Structural diagram of TBC-1269.
flammation [19]. Blockade of one selectin can lead to were kept well hydrated with IP saline and were kept
at a constant temperature (37C). After the renal arterycompensatory inflammation conducted by the other se-
lectins. Due to shared ligands, an alternative approach clamp was removed, the incision was sutured and the
animal was allowed to recover.is to target selectin ligands. Recently, it was found that
administration of PSGL-1, a soluble P-selectin ligand,
Reagentsattenuated post-ischemic renal dysfunction in a cold in
situ perfusion model in rats [20]. The selectin ligand antagonist TBC-1269, was graciously
donated by Texas Biotechnology Corporation (Houston,The present study was designed to test the hypothesis
that a novel small molecule antagonist of all three selec- TX, USA). TBC-1269 {1,6-Bis [3-(3-carboxymethylphe-
nyl)-4-(2--D-mannopyranosyloxy)-phenyl] hexane} is atin ligands (TBC-1269) (Fig. 1) [21, 22] would mitigate
post-ischemic renal damage. Intervention with TBC- small molecule antagonist of E-, P- and L-selectin bind-
ing to their ligand, sialyl Lewis X (sLeX). TBC-1269 is a1269 was compared with a parallel but complementary
approach to selectin blockade using a combination of non-oligosaccharide glycomimetic [21]. The structure of
TBC-1269 (Fig. 1) reveals two mannose and two carbox-anti-selectin monoclonal antibodies. In addition to evalu-
ating the effects of selectin blockade in moderate IRI, ylic acid groups in a configuration to mimic the dimeric
conformation of sialyl-Lewis X (s-di-LeX). TBC-1269where a pathogenic role of inflammation is relatively
blocks E-, P- and L-selectin and is approximately sixfold,established, we studied selectin blockade in a model of
50-fold and sixfold more potent, respectively, than thesevere IRI to widen the possible clinical relevance of
natural ligand (sLeX) in inhibiting the binding of recom-the study findings.
binant E-, P- and L-selectin to sLeX containing HL-60The novel findings of this study include (1) small mole-
cells in a static state [21]. Specific antibodies directedcule selectin ligand antagonism attenuates post-ischemic
against E- or P-selectin were RMP-1 (IgG2a) anti-ratrenal dysfunction, (2) mortality associated with severe
P-selectin and RME-1 (IgG1) anti-rat E-selectin, respec-renal IRI is significantly reduced by small molecule selec-
tively. These antibodies were selected because they blocktin antagonism, (3) timing of selectin ligand blockade is
adhesion function of their respective antigens in vitrocrucial to optimizing renal protection, and (4) combined
[23, 24] and leukocyte rolling in vivo [25, 26].P- and E-selectin antagonism protects from renal IRI.
Treatment protocols
METHODS
Four experimental groups along with their own group
Renal ischemia model of control saline-treated rats were investigated.
(1) One group of rats (N  5) was injected IV withAn established model of renal IRI was used [10, 13,
19]. Male 150 to 200 g Sprague-Dawley rats were pur- TBC-1269 at the time of ischemia during moderate IRI,
and received a SC injection of TBC-1269 one hour post-chased from Harlan Sprague-Dawley (Indianapolis, IN,
USA). Animals were anesthetized with IP sodium pento- ischemia. TBC-1269 was administered at a concentration
of 25 mg/kg based on a previous dosing studies [21].barbital, 50 mg/kg. To produce the model of single-kid-
ney IRI, an abdominal incision was made and the renal (2) One group of rats (N  5) was injected IV with
TBC-1269 (25 mg/kg) at one and two hours after moder-pedicles were bluntly dissected. A microvascular clamp
was placed on the right renal pedicle for 30 minutes ate IRI. This delayed treatment regimen was performed
to simulate the clinical situation in which patients would(moderate ischemia) or 45 minutes (severe ischemia)
in rats, while the left kidney underwent simultaneous have access to treatment only after reperfusion began.
(3) One group of rats (N  5) was injected IV withnephrectomy. During the ischemia procedure, animals
Nemoto et al: Selectin ligand inhibition in renal IRI 2207
TBC-1269 (25 mg/kg) at the time of severe IRI (45 min represented more severe damage (maximum score 4):
0 normal kidneys; 1minimal necrosis (5% involve-renal artery clamping) and received a SC injection of
TBC-1269 one hour post-ischemia. ment); 2  mild necrosis (5 to 25% involvement); 3 
moderate necrosis (25 to 75%); 4  severe (75%(4) One group of rats (N  5) was injected IV with a
combination of E- and P-selectin antibodies, each at a dose involvement).
of 2 mg/rat, at the time of moderate IRI. A second injec-
Immunohistochemical stainingtion of antibodies at the same concentration was adminis-
tered via the tail vein at five hours post-ischemia to main- Immunohistochemical analysis was performed on kid-
ney tissue samples obtained at 0, 6, 24, 72 and 1 weektain saturation levels. Selectin antibodies were used in
this study to compare the effects of selectin blockade postischemia. Tissue sections prepared as described above
for routine histology were affixed to capillary gap glasswith selectin ligand blockade using TBC-1269 on renal
IRI. Antibody blockade of L-selectin was not included microscope slides (Ventana Medical Systems, Inc., Tuc-
son, AZ, USA), dried at 60C for one hour, and deparaf-in this study, as we have previously shown a lack of pro-
tection from renal IRI in L-selectin deficient mice [19]. finized. The tissue sections were incubated for 20 minutes
in a 1:10 citrate buffer solution (Dako Corporation, Car-Each experimental group outlined above was matched
with control saline-treated animals that were operated pinteria, CA, USA) in a steam environment to enhance
antigen availability, and then incubated in the same bufferon simultaneously. An ischemia time of 30 minutes was
chosen because it produces a sublethal kidney injury solution for an additional 20 minutes at room temperature.
Sections (4m) of frozen tissue obtained also at 72 hourssimilar to that seen in human IRI with ischemic acute
tubular necrosis and experimental models have shown post-ischemia were prepared on a cryostat, fixed in ice-
cold acetone for 10 minutes, and allowed to air dry.a “window” of protection against inflammation in IRI
with this clamp time [8, 27]. The severe model of IRI Paraffin and frozen sections were rinsed in phosphate
buffered saline, pH 7.3/0.2% Tween-20 (PBS/T) to en-(45 min ischemia) was used to simulate injury seen in
patients who have very significant post-ischemic renal hance flow in the capillary gap. PBS/T was used to rinse
the sections between all steps of the protocol. All re-dysfunction that is associated with prolonged patient
morbidity and occasionally death, and in which there is agents used in the immunohistochemical procedure were
made in PBS/T supplemented with 0.5% crystallineless evidence for an important role for leukocyte adhe-
sion molecules. grade bovine serum albumin (BSA; Sigma Chemical Co.,
St. Louis, MO, USA) as a protein carrier.
Assessment of post-ischemic renal function Immunohistochemistry was performed using a Tek-
Mate 500 automated system (Ventana Medical Systems).Blood samples were obtained from the tail vein at 24,
48 and 72 hours post-ischemia. Serum creatinine (mg/dL) Endogenous biotin activity was blocked using a biotin
blocking system (Dako), and tissue was then rinsed wellwas measured using a Synchron LX20 Clinical System
(Beckman Culture Inc., Fullerton, CA, USA). Previous in PBS/T. Tissue sections were incubated in a 1:75 solu-
tion of normal serum (goat serum for anti-myeloperoxi-studies have validated the rise of serum creatinine in this
model as a marker of glomerular filtration rate (GFR) dase antibody and horse serum for anti-CD4 antibody;
Vector Laboratories, Burlingame, CA, USA) for 20 min-[10]. We have found that serum creatinine values in mice
measured up to 72 hours post-ischemia correlate with utes at room temperature. The serum was then removed
and the primary antibody was applied. Rabbit anti-glomerular filtration rates measured by inulin clearance
(abstract; J Am Soc Nephrol 11:606A, 2000). myeloperoxidase antibody (Dako) at a concentration of
1:1600 or mouse anti-CD4 antibody (Serotec, Indianapo-
Assessment of post-ischemic tubular injury lis, IN, USA) at a concentration of 5 g/mL was applied
for 90 minutes at room temperature. Type specific con-At 24 hours and one week post-ischemia, kidneys were
dissected from rats and coronal tissue slices were fixed in trol antibodies were used to distinguish background
staining. Biotin-conjugated species-specific secondary10% formalin and processed for histology using standard
techniques. Tissue was embedded in paraffin and 4 m antibody (Vector Laboratories) was then applied at a
concentration of 2.25 g/mL for 45 minutes at roomslices were cut. Basement membranes and other oxidiz-
able 1,2-diol containing structures were visualized using temperature. This was followed by endogenous peroxi-
dase exhaustion using 3% H2O2 in absolute methanolperiodic acid-Schiff (PAS). Sections were counterstained
in Mayers hematoxylin and cover slipped using a syn- (three changes of 5 min each). The sections were treated
with a peroxidase tagged avidin-biotin complex (Vectorthetic mounting medium. The stained tissue sections
were then reviewed in a blinded fashion by a renal pa- Laboratories) for 45 minutes at room temperature and
rinsed well in buffer. Antigenic sites were demonstratedthologist and nephrologist, and scored with a previously
described semiquantitative scale designed to evaluate using DAB as the chromagen and 1% nickel chloride
was added for enhancement. The sections were counter-the degree of tubular necrosis [10, 13]. Higher scores
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Fig. 2. Protective effect of early ischemia-reperfusion injury (IRI) Fig. 3. Effect of post-IRI treatment with TBC-1269 on renal function
treatment with TBC-1269 on renal function post-moderate ischemia in after moderate ischemia in rats. Serum creatinine levels at 24, 48 and
rats. Serum creatinine levels at 24, 48 and 72 hours post-ischemia in 72 hours post-ischemia in () control and () rats treated with TBC-
() control and () rats treated with TBC-1269 prior to 30 minutes of 1269 after 30 minutes of ischemia (N  5 per group).
ischemia (N  5 per group, *P  0.05).
stained in eosin, dehydrated, rinsed in xylene, and
mounted using a synthetic mounting medium. Ten ran-
domly selected high power fields (magnification 400)
at the major site of leukocyte accumulation, the corti-
comedullary junction, were counted for positively stained
cells. Total counts were compared between control rats
and TBC-1269 treated rats.
Statistical analysis
Data are expressed as mean  SEM. Comparisons of
group means were performed using the Student t test.
Mortality rates were compared using the Fisher Exact
Test. A P  0.05 was considered statistically significant.
Fig. 4. Effect of early IRI treatment with TBC-1269 on renal functionRESULTS
after severe ischemia in rats. Serum creatinine levels at 24, 48 and 72
Post-ischemia renal function in TBC-1269 treated rats hours post-ischemia in () control and () rats treated with TBC-1269
prior to 45 minutes ischemia (N  5 per group).Renal function in rats treated with TBC-1269 during
moderate ischemia (30 min renal artery clamping) is
shown in Figure 2. Serum creatinine (SCr) was signifi-
cantly reduced at 24 hours post-ischemia in TBC-1269 TBC-1269 treated or control groups was not significantly
treated rats, compared to that in control rats (1.4  0.4 different.
vs. 2.7  0.2 mg/dL, respectively; P  0.05). In contrast,
MortalitySCr in rats treated with TBC-1269 starting one hour post-
moderate ischemia were not significantly different at 24 Severe ischemia (45 minutes clamping) led to high
hours (2.8  0.2 vs. 2.8  0.1 mg/dL), 48 hours (1.8  mortality in control rats. Survival rates of TBC-1269
0.5 vs. 1.9 0.4 mg/dL) or 72 hours (1.3 0.3 vs. 1.4 0.3 treated and control rats with severe IRI are shown in
mg/dL) post-ischemia compared to control rats (Fig. 3). Figure 5. At 24 hours post-ischemia, all rats in each group
Renal function in rats was studied in a more severe were alive. However, mortality at 48 hours was 60% in
model of IRI produced by 45 minutes of renal artery the control group versus 0% in TBC-1269 treated rats.
clamping. Data from control rats and rats treated with By 72 hours, all five control rats had died, while only
TBC-1269 during severe ischemia are shown in Figure 4. one of the five TBC-1269 treated rats had died (P 
0.05).Post-ischemic SCr obtained from surviving rats in both
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Fig. 6. Protective effect of early IRI treatment with E- and P-selectinFig. 5. Decreased mortality of TBC-1269 treated rats following severe
antibodies on renal function post-moderate ischemia in rats. Serumrenal IRI. Survival of TBC-1269 treated () and control () rats follow-
creatinine levels at 24, 48 and 72 hours post-ischemia for () controling 45 minutes of ischemia (*P  0.05).
and () E-selectin and P-selectin antibody treated rats subjected to 30
minutes of ischemia (N  5 per group, *P  0.05).
Post-ischemic renal function in antibody-treated rats As demonstrated in the postischemic tissue at 72 hours
and one week, no significant difference in MPO posi-To evaluate the effects of antibodies to E- and
tively stained cells was observed between the TBC-P-selectins on renal IRI, one group of rats were treated
treated rats and saline-treated rats.with specific anti-rat antibodies to both selectins ten min-
Recent studies have indicated that E- and P-selectinsutes prior to 30 minutes of ischemia, and again at five
participate in recruitment of T-helper 1 (Th1) T cells tohours post-ischemia. SCr was significantly lower in selec-
areas of inflammation [30]. In addition, we have recentlytin antibody-treated rats than in control rats at 24 hours
demonstrated a direct role for T cells in the pathogenesis(1.9  0.3 vs. 2.7  0.2 mg/dL, respectively; P  0.05)
of experimental renal IRI [31]. Thus, we also evaluatedpost-ischemia (Fig. 6).
infiltration of CD4	 cells into the post-ischemic rat kid-
Immunohistochemistry ney. Post-ischemic renal tissue treated with anti-CD4
antibody was stained and the number of CD4	 cellsIt can be difficult to accurately identify leukocyte infil-
counted (Fig. 7 e and f, and Fig. 9). At 24 hours, theretration into postischemic rat kidney without special
were moderate numbers of CD4 cells in the outer me-stains. The staining for myeloperoxidase (MPO) positive
dulla, but no significant difference in CD4 counts be-cells is shown and represented by large black arrows in
tween control rats and rats treated with TBC-1269 duringFigure 7 panels b and c. Smaller arrows in Figure 7b
moderate ischemia (Fig. 9). In both groups the numberrepresent the red blood cell sludging that occurs follow-
of tissue CD4	 cells increased significantly between 24ing renal IRI. Myeloperoxidase positive cells were quan-
hours and one week post-ischemia, and CD4	 countstified in post-ischemic kidney sections as an index of
were not different between the two groups at one weekneutrophil infiltration (Fig. 8) [8, 28]. However, the re-
post-ischemia (Fig. 9).
cent report by Ysebaert et al demonstrated that MPO
also can stain macrophages [29]. In saline-treated control Assessment of postischemic tubular injury
rats, the number of MPO-positive cells increased be- Significant tubular injury was observed at 24 hours
tween 24 and 72 hours post-ischemia, and then resolved post-ischemia in tissue from control rats (Fig. 10). This
to low levels characteristic of normal kidneys (5 cells/ was characterized by extensive tubular epithelial necrosis
HPF) at one week post-ischemia (Fig. 8). In rats treated and sloughing of epithelial cells into the lumens. Cells
with TBC-1269 during moderate ischemia, which were that were not necrotic generally lacked a PAS-positive
protected from IRI, MPO counts were not decreased at brush border on the luminal surface. Many of the tubules
24 hours post-ischemia, compared to counts in control were dilated with occasional areas of denudation of base-
rats. At 72 hours and one week post-ischemia, MPO ment membranes. A few tubules contained casts in the
counts were not different between the saline-treated or lumens consisting mostly of necrotic material. Tubular
TBC-1269 treated groups. We also studied kidney taken necrosis scores are presented in Figure 11. At 24 hours
at six hours postischemia to see if neutrophil infiltration post-ischemia there was a significant protection from
tubular damage in TBC-1269 treated rats.was effected early in the postischemic period (Fig. 8).
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Fig. 7. Myeloperoxidase and CD4	 cell staining of post-ischemic tissue following 30 minutes of ischemia. (a) Control rat kidney tissue at 24 hours
post-ischemia with application of a control antibody. (b) Control rat kidney tissue at 24 hours post-ischemia with application of the myeloperoxidase
(MPO) specific antibody. (c) TBC-1269 treated rat kidney tissue at 24 hours post-ischemia with application of the MPO specific antibody. Large
arrows represent MPO-stained cells and small arrows represent red blood cell sludging in the postischemic kidney. (d) Control rat kidney tissue
at one week post-ischemia with the application of a control antibody. (e) Control rat kidney tissue at 1 week post-ischemia with the application
of a specific CD4	 antibody. ( f ) TBC-1269 treated rat kidney tissue at one week post-ischemia with the application of a specific CD4	 antibody
(magnification 50). Large arrows represent CD4	-stained cells.
DISCUSSION other selectins. Interestingly, TBC-1269 effectively at-
tenuated renal IRI only when given early during theThis study demonstrates the protective effect of a
initiation of the ischemic injury. Administration ofnovel, small molecule-based approach to blocking selec-
TBC-1269 at one hour and again at two hours post-tin ligands in renal IRI. Our results highlight the impor-
ischemia did not preserve post-ischemic renal function.tance of early treatment for most effective outcome. In
These results suggest that selectin-mediated events thataddition, antibody treatment directed against P- and
promote post-ischemic renal dysfunction, and that areE-selectin also affords renal protection during IRI.
blocked by TBC-1269, occur during the time of ischemiaThe selectin antagonist TBC-1269, which blocks bind-
or in the immediate post-ischemic period. This is consis-ing of all three selectins to their sLeX receptors, signifi-
tent with the work by Kelly et al, who found the delayedcantly reduced post-ischemic renal dysfunction in rats
treatment with integrin and ICAM blockade was not aswith moderate renal IRI. Thus, targeting a common li-
effective as early treatment [8]. Moreover, these resultsgand sLeX for the three known selectins may be a more
suggest that a potential benefit of selectin ligand antago-effective therapeutic strategy than targeting an individ-
ual selectin whose function can be compensated by the nism to reduce DGF might be maximized by starting to
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Fig. 9. Effect of TBC-1269 treatment on positive CD4 cells in the post-Fig. 8. Effect of TBC-1269 treatment on positive myeloperoxidase cells
ischemic kidney following 30 minutes of ischemia. CD4 counts per highin the post-ischemic kidney following 30 minutes of ischemia. Myeloperoxi-
power field in () control and () TBC-1269 treated rats at 24 hoursdase counts per high power field in () control and () TBC-1269 treated
and one week post-ischemia (*P  0.05).rats at 6, 24, and 72 hours, and one week post-ischemia (*P  0.05).
treat the organ at procurement rather than initiating phages, so our approach may have identified infiltration
of both these is cells rather than PMNs alone [29]. Wetreatment after anastamosis and thus reperfusion. In na-
tive kidney IRI or high-risk aortic bypass surgery, a po- found, as many others have, that there is an increase
in MPO staining in postischemic rat kidney [8, 11, 29].tential benefit might be maximized by starting treatment
prior to releasing the clamps. However, we did not observe a decrease in MPO counts
in the TBC-1269 treated group even when evaluated atAlso of potential clinical importance was the finding
that selectin ligand antagonism significantly reduced different time points. This observation is consistent with
our previous findings in asthma models [32, 33] and bymortality in rats with severe renal IRI produced by the
45-minute clamping of the renal artery. Though mortality others in a glomerulonephritis model [34], that leukocyte
adhesion blockade in vivo can have a physiologic impactassociated with transplant renal IRI is normally low, it
is high in patients with native kidney IRI. Even though on organ function independent of leukocyte infiltration
into tissue. Our current studies were not designed tothe decrease in SCr in the TBC-1269 group did not appear
to be significantly different from saline treated group, it elucidate the leukocyte infiltration-independent mecha-
nisms for leukocyte adhesion molecule effects on tissue.is important to note that these results are skewed by the
fact that blood samples were taken from surviving rats The mechanisms by which leukocyte adhesion blockade
protects from organ injury independent of abrogatingonly. Thus, the sicker rats in the saline treated group
that died early did not have their SCr values included in leukocyte infiltration are not known. It is conceivable
that selectin ligand blockade might have attenuated IRIthe analysis. Another possibility that explains a large
improvement in mortality but not SCr is that small differ- by altering leukocyte signaling and other functions rather
than by simply preventing leukocyte accumulation. Inences in GFR can potentially make a difference in pa-
tient survival. Thus, we cannot exclude the possibility support of this possibility is the recent study that shows
that TBC-1269 can significantly attenuate allograft rejec-that small changes in GFR occurred in the TBC-1269
treated rats with severe IRI that were not detected by tion of rat kidneys, suggesting that it has important ef-
fects on leukocyte, and particularly T cell signaling (ab-differences in serum creatinine. It also is possible that
systemic inflammation, which could predispose to mor- stract; J Am Soc Nephrol 11:672A, 2000).
We also evaluated the effects of TBC-1269 on T celltality, was limited by TBC-1269.
Due to the well-recognized role of selectins in mediat- infiltration into postischemic kidney. A number of inves-
tigators have proposed that T cells may be importanting neutrophil rolling on the endothelium in vitro, we
evaluated infiltration of leukocytes into postischemic tis- mediators of post-ischemic tissue injury [31, 35]. More-
over, it has been reported that E- and P-selectins cansue. Because it can be difficult to quantify polymorpho-
nuclear neutrophils (PMNs) in postischemic rat kidney participate in recruitment of Th1 cells to an area of
inflammation [30, 36]. Results of our immunohistochem-by direct hematoxylin and eosin staining, myeloperoxi-
dase staining was used to detect PMNs. A recent paper istry analysis, however, indicated no differences in CD4
cell numbers between rats treated with TBC-1269 andhas suggested that MPO stains both PMNs and macro-
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Fig. 10. Effect of TBC-1269 treatment on the morphology of the post-ischemic kidney following 30 minutes of ischemia. (A) Normal rat kidney
tissue. (B) Sham operated rat kidney tissue. (C) Control rat kidney tissue at 24 hours post-ischemia following moderate IRI. (D) TBC-1269 pre-
IRI treated rat kidney tissue at 24 hours post-ischemia following moderate IRI. (E) Control rat kidney tissue at one week post-ischemia following
moderate IRI. (F ) TBC-1269 early IRI treated rat kidney tissue at one week post-ischemia following moderate IRI (magnification 100).
our control rats, suggesting at least that TBC-1269 did in combination, significantly reduced post-ischemic se-
rum creatinine level in rats with moderate renal IRI,not attenuate renal IRI by suppressing CD4 cell infiltra-
tion postischemia. suggesting a role of E-selectin or P-selectin, or both, in
post-ischemic renal dysfunction. E-selectin is typicallyAntibodies directed against E- and P-selectins, given
Nemoto et al: Selectin ligand inhibition in renal IRI 2213
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